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Objective: To present the preliminary results of treating a series of Chinese patients with painful bladder
syndrome/interstitial cystitis (PBS/IC) using intravesical hyaluronic acid (HA).
Materials and methods: A series of 13 patients with PBS/IC received ﬁrst-line therapy followed by HA
once-a-week for 4 weeks and then once monthly for 4 months. Outcomes measured included O'Leary-
Sant Interstitial Cystitis Symptom Index (ICSI) and Interstitial Cystitis Problem Index (ISPI) scores, voiding
frequency, and bladder capacity.
Results: ISPI and ICSI scores were signiﬁcantly (p < 0.001) decreased after treatment [median change
(interquartile range): ISPI ¼ 2 (2e3); ICSI ¼ 3 (2e3)]. Voiding frequency and functional bladder capacity
were signiﬁcantly (p < 0.001) decreased [median change: 7 (6e8) times/d] and increased [median
change: 190 (116e233) mL], respectively after treatment.
Conclusion: Our case series supports the efﬁcacy of intravesical HA in the treatment of PBS/IC.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Painful bladder syndrome/interstitial cystitis (PBS/IC) is a
chronic bladder disease and usually presents as frequency, urgency,
nocturia, and suprapubic pain [1]. Although the pathogenesis of
PBS/IC is not completely clear, it may involve a defective mucin
glycosaminoglycan layer of the bladder urothelium [2].
The glycosaminoglycan layer is secreted by the transitional
epithelium and is also bound to its surface. The glycosaminoglycan
layer consists of long, linear, and highly negatively charged poly-
saccharides composed of a variable number of repeating disac-
charide units. The layer can protect the bladder wall from injury,
microorganisms, and toxins [2]. The loss of the glycosaminoglycan
layer is pathophysiologically linked with many different chronic
inﬂammatory bladder diseases, for example, recurrent urinary tract
infection, chemical or radiation cystitis, and PBS/IC [3]. The loss ofion Hospital, Tongji Medical
ology, 1277 Jiefang Avenue,
@163.com (M. Chen).
bstetrics & Gynecology. Publishedthe watertight function of the urothelium may allow both the
normal and abnormal constituents of urine to directly contact the
subepithelial layers, resulting in inﬂammation and delayed healing
of the damaged urothelial layer. Consequently, some noxious sub-
stances in urine may activate submucosal nerve ﬁlaments, thus
accounting for symptoms of pain, urgency, and urinary frequency.
The relevant components of the glycosaminoglycan layer
include hyaluronic acid (HA), chondroitin sulfate, heparin sulfate,
and keratin sulfate [4]. HA is widely found in connective, epithelial,
and neural tissues. It is one of the main components of the extra-
cellular matrix that is involved in cell proliferation and migration.
In the bladder urothelium, HA contributes an important compo-
nent of the glycosaminoglycan layer and constitutes a protective
barrier [2e4].
According to the physiological function of the glycosamino-
glycan layer, early repair of the glycosaminoglycan layer may help
avoid subsequent chronic bladder inﬂammation by improving the
integrity and function of the bladder lining. As one of the relevant
components of the glycosaminoglycan layer, HA has been reported
to be effective in a number of studies for the treatment of PBS/IC,
but others have found HA to be no better than a placebo [5]. Theby Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient demographics and clinical characteristics (N ¼ 13).
Age (y) 26.0 (21.0e32.0)*
Sex
Female 11 (84.6)
Male 2 (15.4)
History of ketamine exposure
No 8 (61.5)
Yes 5 (38.5)
Sitting on the toilet for several hours & severe suprapubic
or perineal pain on changing position
No 10 (76.9)
Yes 3 (23.1)
Urodynamic examination
No 6 (46.2)
Yes 7 (53.8)
Disease course (mo) 36.0 (29.5e40.0)
Follow-up time (mo) 5.0 (5.0e6.0)
Symptoms after treatment
Resolved completely 10 (76.9)
Improved 3 (23.1)
Data are presented as n (%) or median (interquartile range).
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[6,7]. Clearly, further evidence is needed to establish whether HA is
an effective treatment for PBS/IC.
Here we present our preliminary results treating a series of
Chinese patients with PBS/IC using HA. In addition, we perform a
systematic review of the literature concerning the efﬁcacy of HA for
treating PBS/IC.
Materials and methods
Patients
Patients with PBS/IC who were treated at our hospital-based
clinic in Wuhan Union Hospital, Wuhan, China between January
2009 and February 2010 and met the following inclusion criteria
were included in this study: (1) experience of long-term (> 9
months) urinary urgency, increased urinary frequency, and supra-
pubic bladder area pain aggravated by delayed urination and
diminished after voiding; and (2) meeting the Interstitial Cystitis
Data Base requirements for ruling out confounding diseases [8].
Exclusion criteria for PBS/IC included the following: (1) a history
of or current genitourinary tuberculosis; (2) a history of urethral
cancer; (3) a history of bladder malignancy, high-grade dysplasia,
or carcinoma in situ; (4) for males: a history of or current prostate
cancer or current bacterial prostatitis during the previous 6
months; and for females: a history of or current ovarian, vaginal, or
cervical cancer during the previous 3 years or current vaginitis, clue
cells, trichomoniasis, or yeast infection; (5) a history of bacterial
cystitis during the previous 3 months; (6) a history of active herpes
during the previous 3 months; (7) a history of antimicrobial use for
urinary tract infections during the previous 3 months; (8) a history
of treatment with cyclophosphamide; (9) a history of radiation
cystitis; (10) a history of neurogenic bladder dysfunction; (11) a
history of bladder outlet obstruction; (12) a history of bladder,
ureteral, or urethral calculi during the previous 3 months; (13) a
history of urethritis during the previous 3 months; (14) a history of
treatment with urethral dilation, cystometrogram, or bladder
cystoscopy under full anesthesia or bladder biopsy during the
previous 3 months; and (15) a history of treatment for augmenta-
tion cystoplasty, cystectomy, cytolysis, or neurectomy.
The study was reviewed and approved by the Institutional Re-
view Board of Wuhan Union Hospital.
Treatment and assessments
All patients were previously treated conservatively, including
dietary advice to avoid foods rich in potassium, alcohol, and spicy or
irritant foods containing black pepper or capsaicin. Patients were
instructed to gradually delay urination, control water intake, and to
practice pelvic ﬂoor muscle exercises. After anti-inﬂammatory
treatment, all patients received intravesical therapy with HA
40 mg (Cystistat, Bioniche Life Sciences Inc., Ireland) with 50 mL
phosphate-buffered saline solution once-a-week for 4 weeks and
thereafter once monthly for 4 months.
Before treatment and 2 weeks following treatment, all patients
were asked to complete a 3-day voiding diary so we could evaluate
the voiding frequency and functional bladder capacity and the
Chinese version of O'Leary-Sant ICSI and ISPI to assess therapeutic
outcomes [9].
Data analysis
Continuous variables are presented asmedianwith interquartile
ranges (IQR, 25th and 75th percentiles), and categorical variables are
presented as frequencies and percentages. Pre- and post-treatmentdifferences in ICSI and ISPI, voiding frequency, and functional
bladder capacity were compared using a Wilcoxon signed-rank
test. Statistical analyses were performed using SAS software
version 9.2 (SAS Institute Inc., Cary, NC, USA). A two-tailed p < 0.05
indicated statistical signiﬁcance.
Results
We reviewed the records of 16 patients and excluded three
patients who presented with positive urine culture tests who were
then treated with antibiotics. The study cohort included 13 patients
(11 females, 2 males). The demographic and clinical characteristics
of our patients are summarized in Table 1. Routine urinalysis
ﬁndings were normal in all 13 patients. The 10 patients who
received cystoscopy and biopsy before treatment showed inﬂam-
matory cells and small numbers of plasma cells in the submucosal
layer and intermuscular tissue, which are changes indicative of
chronic cystitis. Speciﬁcally, pretreatment cystoscopic ﬁndings
included dilated small blood vessels, multiple punctate hemor-
rhages on bladder mucosa, or notable congestion after bladder
ﬁlling. No Hunner ulcers were seen. After treatment, we did not use
cystoscopy to evaluate improvement.
The results of the before and after treatment assessments are
summarized in Table 2. Signiﬁcant improvements were seen from
before treatment compared with after treatment in the assess-
ments of ICSI, ISPI, voiding frequency, and functional bladder ca-
pacity (all p < .001).
Systematic review
Search strategy
Medline, the Cochrane database, EMBASE, and Google Scholar
were searched from inception until 31 August 2014 using the
following keywords: “painful bladder syndrome,” “interstitial
cystitis,” “hyaluronic acid,” or “glycosaminoglycan.” Reference lists
of pertinent studies were hand-searched to identify other poten-
tially relevant studies.
Selection criteria
Studies were considered for inclusion in the review if study
patients had a history of PBS/IC and received treatment with
Table 2
Comparison of assessments before and after treatment with hyaluronic acid for painful bladder syndrome/interstitial cystitis (N ¼ 13).
Assessment Before treatment After treatment Absolute difference p*
Voiding frequency (times/d) 17 (15e19) 10 (9e12) 7 (6e8)** <0.001
Functional bladder capacity (mL) 68 (54e80) 270 (170e317) 190 (116e233)*** <0.001
O'Leary-Sant Interstitial Cystitis Symptom Index 8 (8e9) 6 (5e6) 3 (2e3)** <0.001
O'Leary-Sant Interstitial Cystitis Problem Index 9 (8e10) 7 (7e7) 2 (2e3)*** <0.001
Data are presented as median (interquartile range).
* Wilcoxon signed-rank test.
** Decreased after treatment.
*** Increased after treatment.
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ered, and those that did not report outcomes after intravesical
treatment with HA were excluded.Study selection and data extraction
Studies were identiﬁed by two independent reviewers. When
there was uncertainty regarding eligibility, a third reviewer was
consulted. The following information and data were extracted from
eligible studies: the name of the ﬁrst author, year of publication,
study design, number of participants in each study group, partici-
pants' age and sex, HA dose and regimen, length of follow-up,
outcome parameters, and key results, including cystoscopic
ﬁndings.Literature search
A ﬂow chart for the selection of trials is given in Fig. 1. Initial
screening identiﬁed 135 articles; 98 were excluded after title and
abstract screening. Among the 37 remaining articles that under-
went full-text screening, 14 were excluded for the reasons stated in
Fig. 1, leaving 23 included for the systematic review [10e32].Study characteristics and outcomes
Among the 23 included studies, less than half of the studies (9/
23) were comparative studies (summarized in Table 3), whereas the
other studies were single-arm cohort studies (summarized in
Table 4). Only three comparative studies were of randomized
design [14,25] and only one comparative study evaluated cysto-
scopic results [24]. The outcomes of the included studies are
summarized in Tables 3 and 4.Fig. 1. Flow diagram of study selection. PBS/IC ¼ painful bladder syndrome/interstitial
cystitis.Discussion
Herein we describe a small series of patients with PBS/IC who
were treated with intravesical HA. This is one of a few reports
regarding the use of intravesical HA for the treatment of PBS/IC in
Chinese patients. Because ethnic/racial differences can affect the
way patients with various diseases respond to different treatments,
we believe our ﬁndings are of interest, despite the small number of
patients included in our analyses. Of note, we observed signiﬁcant
improvement in all outcome measures assessed after treatment
with HA, speciﬁcally ISPI and ICSI scores, voiding frequency, and
maximum bladder capacity (Table 2).
In the systematic review, the number of patients in each treat-
ment group or study was typically around 15e20 but ranged from 3
to 121. Most patients were approximately 50 years of age. The HA
dose in most (16/23) studies was 40 mg. HA 40 mL was given with
chondroitin sulfate in six studies. The HA treatment regimen varied
considerably between studies. The most commonly used regimen
was HA weekly for 4 weeks and then monthly for 2e6 months.
Intravesical instillation timewas reported in 11 of 19 studies andwas
most commonly 1 hour in duration. The duration of follow-up varied
considerably among studies and ranged from 5months to 4.9 years;
however follow-upbetween6monthsand1yearwasmost common.
The types of outcomes measured also varied among studies
(Tables 3 and 4). ICSI, ICPI, visual analogue scale (VAS) pain,
bladder capacity, and voiding frequency were the more commonly
assessed outcomes. All studies that assessed ICSI and ICPI scores
reported improvements after treatment with HA
[15,17,18,24,25,29e32]. Similarly, improvements in pain (VAS or
other means of assessment) [10e12,16e18,20,21,24,25,29e32],
bladder capacity [19,24,25,28e32], and voiding frequency
[12,13,16e18,20,23,24,29e32] after treatment with HA were
consistently reported. Cystoscopic ﬁndings were reported in four
of the 23 studies and were consistently positive regarding the
effects of HA, including resolution of ulceration, inﬂammation, and
submucosal ectasia, along with improvements in the appearance
of bladder mucosa [17,24,26,28].
Despite between-study differences in HA dose and regimen and
length of follow-up [10e32], the literature review revealed that the
majority of outcomes improved after intravesical HA and were also
consistent with our results. Although there is a distinct lack of data
from high-quality clinical trials (i.e., randomized controlled trials),
the considerable body of evidence from prospective studies now
supports the use of intravesical HA as an effective treatment for PBS/
IC.
Both our case series and systematic review have a number of
limitations that must be acknowledged. Clearly, the statistical re-
sults associated with our case series must be interpreted with
caution because of the small sample size. A further limitation is the
relatively short length of follow-up. Other studies, however, have
demonstrated that treatment with HA is associated with main-
tained long-term improvement [18,27e29].
Table 3
Characteristics and results of comparative studies included in the systematic review.
Study Design Comparison groups Dose Frequency Intravesical
time
Patients
(N)
Age
(mean, y)
Follow-up Outcomes measured Key results Cystoscopic
ﬁndings after
treatment
Jiang et al
2014 [31]
N Group 1: HA HA 40 mg Weekly for 4 wk, then
monthly for 5 mo
N/A 33 46.9 N/A Total urinary NGF
& BDNF, VAS for pain
NGF & NGF/Cr levels
signiﬁcantly decreased
after HA treatment, but
urinary BDNF & BDNF/Cr
did not
N/A
Group 2: healthy
control
d d 45 45.9
Gülpınar et al
2014 [29]
R Group 1: HA Group 1:
HA 40 mg
Weekly for 4 wk, then
monthly for 2 mo
1 h 15 43.5 24 mo ICSI, ICPI, VAS for pain,
frequency, global
response assessment
ICSI, ICPI, VAS & frequency
were signiﬁcantly lower
in HA þ EMDA in mo 6
& mo 12, but not in mo
1 & mo 24
N/A
Group 2: HA þ EMDA Group 2:
HA 40 mg
þ EMDA
25 min 16 42.8
Lai et al
2013 [25]
R Group 1: Weekly
for 4 wk, then
monthly for 5 mo
HA 40 mg Group 1: Weekly for
4 wk, then monthly for
5 mo
N/A 29 47.9 N/A ICSI, ISPI, VAS pain,
QoL-I, bladder capacity,
voiding frequency,
nocturia, maximum
ﬂow rate, voided volume,
postvoid residual volume
- ICSI, ICPI, VAS,
functional bladder
capacity, maximum
ﬂow rate, & QoL-I
signiﬁcantly improved
by 6 mo in both groups
- Postvoid residual,
bladder capacity, voided
volume, & frequency
signiﬁcantly improved
in group 2 only
- Nocturia did not improve
in either group
N/A
Group 2: Biweekly
for 6 mo
HA 40 mg Group 2: Biweekly for
6 mo
30
Lv et al
2012 [24]
N Group 1: HA 40 mg
þ 2% lidocaine
Group 1:
HA 40 mg
þ 2% lidocaine
Weekly for 8 wk, then
monthly for 4 mo
1 h 15 41.3 Mean
7.5 mo
ICSI, ICPI, VAS for pain,
frequency, & urgency,
voiding frequency,
bladder capacity
- Group 1: All parameters
signiﬁcantly improved at
wk 2, wk 4, wk 24, & wk 48
- Group 2: No parameters
improved at wk 2, but all
signiﬁcantly improved at
wk 4, wk 24, & 48
- Group 3: All parameters
signiﬁcantly improved
signiﬁcantly at wk 2 &
wk 4, but not at wk 24
Submucosal
ectasia absent
- Group 1:
73.3% at
wk 48
- Group 2:
66.7% at
wk 48
- Group 3:
6.67% at
wk 24
Group 2: HA 40 mg Group 2:
HA 40 mg
Weekly for 8 wk,
then monthly for 4 mo
15 42.1
Group 3: 2% lidocaine Group 3: 2%
lidocaine
Weekly for 8 wk, then
monthly for 4 mo
15 40.1
Shao et al
2010 [23]
N Group 1: HA 40 mg Group 1:
HA 40 mg
Weekly for 4 wk, then
monthly for 2 mo
N/A 18 55
(median)
N/A Voiding frequency,
bladder capacity, VAS pain
Improvement (25% decrease
in voids/d or decrease in
VAS 2) at 3 mo, 6 mo, & 9 mo
- Group 1: 93%, 78%, 50%
- Group 2: 100%, 33%, 20%
Bladder capacity
- Group 1: Signiﬁcantly
improved at 3 mo, 6 mo,
& 9 mo
- Group 2: Signiﬁcantly
improved at 3 mo & 6 mo
N/A
Group 2: Heparin
12500U þ 100 mg
lidocaine
Group 2:
Heparin
12500U
þ 100 mg
lidocaine
Weekly for 4 wk, then
monthly for 2 mo
15
Group3:
Hydrodistension
Group3:
Hydrodistension
Weekly for 4 wk, then
monthly for 2 mo
11
(continued on next page)
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Table 3 (continued )
Study Design Comparison groups Dose Frequency Intravesical
time
Patients
(N)
Age
(mean, y)
Follow-up Outcomes measured Key results Cystoscopic
ﬁndings after
treatment
Daha et al
2008 [19]
N Group 1: Complete
responders
(VAS ¼ 0e1)
HA 40 mg Weekly for 10 wk N/A 13 50 N/A Maximal bladder capacity - Group 1: Mean max bladder
capacity increased by 17% or
101.5% (depending on test
solution)
- Group 2: Mean max bladder
capacity decreased by 35%
N/A
Group2:
Nonresponders
(decrease in VAS 1)
HA 40 mg Weekly for 10 wk 14
Gupta et al
2005 [15]
N Group 1: PST(þ) HA 50 mL Weekly for 6 wk, then
optional monthly
treatment
40 min 23 49.4 N/A ICSI, ISPI Improvement rate
- All patients: 55%
- Group 1: 74% (ISCI & ISPI)
- Group 2: 22% (ISCI)
N/A
Group 2: PST() HA 50 mL Weekly for 6 wk, then
optional monthly
treatment
13 44.3
Daha et al
2005 [14]
R Group 1:
Cmax<350 mL
HA 40 mg Weekly for 10 wk N/A 32 54 Mean
6 mo
Bladder capacity, VAS
global bladder symptoms
Response rate (decrease in VAS >2)
- Group 1: 84%
- Group 2: 87%
N/A
Group 2:
Cmax 350 mL
HA 40 mg Weekly for 10 wk 16
Leppilahti
et al 2002 [13]
N Group 1: Long-term
responders (VAS pain
relief)
HA 40 mg 4 weekly 2 h 3 64.5 1 y Voiding frequency
& volume, ICAM-1 Index
ICAM-1 index (pre/posttreatment)
- Groups 1 þ 2: 3.7/3.5
- Group 3: 1.8/2.8
Voiding volume
- Group 1: decrease by 65%
- Group 2: decrease by 21%
- Group 3: no change
Voiding frequency
- Group 1: decrease by 40%
- Group 2: decrease by 26%
- Group 3: decrease by 6%
N/A
Group 2: Short-term
responders
HA 40 mg 4 weekly 5
Group 3:
Nonresponders
HA 40 mg 4 weekly 3
BDNF ¼ brain-derived neurotrophic factor; Cr ¼ creatinine; CS ¼ chondroitin sulfate; Cmax ¼maximum bladder capacity in mL, EMDA ¼ electromotive drug administration; HA ¼ hyaluronic acid; ICAM ¼ intercellular adhesion
molecule; ICPI¼ Interstitial Cystitis Problem Index; ICSI¼ Interstitial Cystitis Symptom Index; NGF ¼ nerve growth factor; PST ¼ potassium sensitivity test; PUF¼ Pelvic Pain and Urinary Frequency Scale; QoL-I ¼ quality of life
index; VAS ¼ visual analogue scale; N/A ¼ not available.
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Table 4
Characteristics and results of single-arm studies included in the systematic review.
Study Dose Frequency Intravesical
time
Patients
(N)
Age
(mean, y)
Follow-up Outcomes measured Key results Cystoscopic ﬁndings
after treatment
Hung et al
2014 [30]
HA 40 mg Weekly for 4 wk,
then monthly for
5 mo
60 min 110 44.3 6 mo VAS for pain, OCSI, ICPI,
PISQ-9
Signiﬁcant improvement
in all parameters at 6 mo
N/A
Giberti et al
2013 [32]
50 mL HA
1.6% þ CS 2.0%
Weekly for 4 wk,
then every 2 wk
for 4 wk, & then
monthly for at
least 3 mo
N/A 20 60.2 Mean, 5 mo ICSI, ICPI,PUF, PHQ-9 ICSI, ICPI,PUFsigniﬁcantly
decreased after HA, but
not PHQ-9
N/A
Costantini et al
2013 [26]
50 mL HA
1.6% þ CS 2.0%
Weekly for 4 wk,
then every 2 wk
for 4 wk, & then
monthly for 2 mo
As long as
possible
9 53.2 6 mo Endoscopic morphological
changes
One patient stopped treatment
because of worsening storage
symptoms
- 6 patients had different
modiﬁcations & improved
clinical results when
macroscopic features of
the bladder mucosa
normalized
- 2 patients had no changes
in cystoscopic ﬁndings or
clinical symptoms
Porru et al
2012 [21]
40 mL HA
1.6% þ CS 2.0%
Weekly for 12 wk,
then biweekly for
6 mo
1e2 h 20 46.6 N/A VAS for pain & urgency,
ICSI, ICPI, Pelvic Pain &
Urgency/Frequency Symptom
Scale
Signiﬁcant improvement in
all parameters at 12 wk
N/A
Cervigni et al
2012 [18]
40 mL HA
1.6% þ CS 2.0%
Weekly for 20 wk,
then every 2 wk
for 4 wk, & then
monthly for 3 mo
1 h 12 52.6 3 y ICSI, ISPI, VAS pain, frequency,
& urgency, PUF symptom scale,
voiding frequency & volume
Improvements in ICSI, ISPI,
PUF symptom scale, VAS scores
No variation between 9 mo &
3 y in voiding frequency
& volume
N/A
Engelhardt et al
2011 [27]
HA 40 mg Weekly until
symptoms resolved
or until treatment
was judged ineffective
N/A 70 48.3 Mean, 4.9 y VAS global bladder symptoms - VAS reduction >2: 85.4%
- VAS reduction <2: 6.3%
- No change: 8.3%
N/A
Riedl et al
2008 [22]
HA 40 mg Weekly until symptom
resolution or until
symptoms improved
& no more instillations
were requested
N/A 121 49.4 6.5 mo VAS global symptoms - 85% symptom improvement
(2 VAS units)
- 55% no or minimal bladder
symptoms (VAS 0e2)
- 84% signiﬁcant improvement
in QoL
- 34.5% had to re-initiate
treatment after stopping,
but 65.5% remained symptom
free for up to 5 y
N/A
Porru et al
2008 [20]
40 mL HA
1.6% þ CS 2.0%
Weekly for 12 wk,
then biweekly for 6 mo
1 h 23 46.6 Mean, 5 mo ICSI, ICPI, Pelvic Pain &
Urgency/Frequency
Symptom Scale, VAS
for urgency & pain,
voiding frequency & volume
Signiﬁcant improvement in all
parameters at 12 wk
N/A
Cervigni et al
2008 [17]
40 mL HA
1.6% þ CS 2.0%
Weekly for 20 wk,
then every 2 wk
for 4 wk, & then
monthly for 3 mo
1 h 23 46.7 Mean, 5 mo ICSI, ISPI, VAS pain, frequency,
& urgency, PUF symptom scale,
urodynamics, voiding frequency
& volume
Signiﬁcantly improvement in all
parameters, except for
urodynamics
- Submucosal vascular ectasia
disappeared in 8/11 patients
- 10/11 patients had markedly
reduced hyperemia of the
bladder mucosa
Ahmad et al
2008 [28]
HA 40 mg Monthly for 2 mo,
then dependent
on symptoms
Mean 3.4 h 23 53.4 Responders:
mean, 15.8 mo;
Nonresponders: N/A
Bladder capacity - 74% response rate (immediate
improvement in symptoms)
- Bladder capacity signiﬁcantly
increased
- Healing of ulceration &
resolution of inﬂammation
occurred in all responders
(continued on next page)
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Table 4 (continued )
Study Dose Frequency Intravesical
time
Patients
(N)
Age
(mean, y)
Follow-up Outcomes measured Key results Cystoscopic ﬁndings
after treatment
Kallestrup
et al 2005 [16]
HA 40 mg Weekly for 4 wk,
then monthly
for 2 mo
Minimum
of 30 min
20 34e80 (range) N/A VAS pain, voiding frequency - 13 patients (65%) were
responders
- 30% strong positive response
- 35% partial responders
- 2 patients developed other
diseases during follow-up
& showed no response to
long-term therapy
N/A
Nordling et al
2001 [12]
HA 40 mg Weekly for 4 wk,
then monthly
for 2 mo
N/A 19 N/A N/A VAS pain, voiding frequency - Approximately 20%
recovered during
treatment
- Most initial responders
experienced continuing
reduction in pain &
frequency of urination
- Nocturia only improved
in the 4 patients who
recovered during treatment
N/A
Porru et al
1997 [11]
HA 40 mg Weekly for 6 wk,
then monthly for
6 mo
N/A 10 45.6 N/A Symptoms score for pain,
frequency, nocturia
- 30% positive response rate
- Signiﬁcant improvement
in all parameters at 2 mo
(maintained at 24 wk)
N/A
Morales et al
1996 [10]
HA 40 mg Weekly for 4 wk,
then monthly for 1 y
N/A 25 50 Mean, 42 wk VAS pain & urgency Progressive improvement in
all parameters
- 56% positive (complete
plus partial) response rate
at wk 4, 71% at wk 12
- Beyond wk 24 there was
a moderate decrease in
treatment effectiveness
N/A
BDNF ¼ brain-derived neurotrophic factor; Cr ¼ creatinine; CS ¼ chondroitin sulfate; Cmax ¼maximum bladder capacity in mL; EMDA ¼ electromotive drug administration; HA¼ hyaluronic acid; ICAM ¼ intercellular adhesion
molecule; ICPI¼ Interstitial Cystitis Problem Index; ICSI¼ Interstitial Cystitis Symptom Index; NGF ¼ nerve growth factor; PHQ-9 ¼ Patient Health Questionnaire 9; PISQ-9 ¼ short form of the Pelvic Organ Prolapse/Urinary
Incontinence Sexual Function Questionnaire; PST ¼ potassium sensitivity test; PUF¼ Pelvic Pain and Urinary Frequency Scale; QoL-I ¼ quality of life index; VAS ¼ visual analogue scale; N/A ¼ not available.
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(Tables 3 and 4). A major limitation is the lack of data from ran-
domized controlled trials. Indeed, only three studies [14,25,29]
eligible for inclusion in our review were randomized trials.
Another limitation of our systematic review is the variability in
characteristics among studies in terms of the HA dose and regimen,
associated treatments, intravesical time, length of follow-up, out-
comes assessed, and methods of assessment. Such variability limits
our ability to draw any speciﬁc conclusions regarding the optimal
implementation of intravesical HA therapy and limits meta-
analysis of available data. There is a real need for well-designed
randomized controlled trials to determine a gold standard for the
use of HA in the treatment of PBS/IC. Finally, we did not examine
quality-of-life outcomes or costs of treatment in either our case
series or systematic review. Both of these are important factors that
should be assessed in future randomized controlled trials that
examine the effectiveness of intravesical HA for the treatment of
PBS/IC.
In conclusion, both the ﬁndings from our case series of 13 pa-
tients and those from our systematic review of literature indicate
that intravesical therapy with HA can provide symptom relief for
Chinese patients with PBS/IC. Importantly, our systematic review
also suggests that different HA doses and regimens may be effec-
tive; again, no gold standard currently guides this treatment
approach. High-quality randomized clinical trials are needed to
identify the optimal means of implementing intravesical HA for the
treatment of PBS/IC. Such studies should include a comprehensive
analysis of outcomes, including changes in quality of life, as well as
the associated costs of treatment.
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